Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07077239 · ClinicalTrials.gov registry record
Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity
A clinical trial of Prostate Cancer (CRPC), sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT07077239 is a study of Prostate Cancer (CRPC) that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07077239, a study of Prostate Cancer (CRPC), is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-treatment time point following magnetic resonance imaging (MRI)-guided or computed tomography (CT)-guided stereotactic body radiotherapy (SBRT) delivered to the prostate bed +/- pelvic lymph nodes. The decision to offer an adaptive treatment will be at the clinician's discretion.
Conditions Studied
Study Locations (1)
California
- University of California at Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-07-17 |
| Est. Completion | 2036-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07077239
The ClinicalTrials.gov registry entry for NCT07077239 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer (CRPC) appearing as the primary indexed condition, and to 0 interventions.
NCT07077239 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07077239 about?
NCT07077239 is a clinical study titled "Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity". Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-treatment time point following magnetic resonance imaging (MRI)-guided or computed tomography (CT)-guided stereotactic body radiotherapy (SBR...
What is the current status of trial NCT07077239?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-07-17. Estimated completion is 2036-08-01.
What conditions does trial NCT07077239 study?
This clinical trial studies the following conditions: Prostate Cancer (CRPC).
Who is sponsoring clinical trial NCT07077239?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07077239 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (CRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.